Cellmid Limited (ASX:CDY) has received its first shipment of 12,000 SARS-CoV-2 rapid diagnostic tests in Sydney.
The Wondfo Biotech manufactured SARS-CoV-2 point of care test (Wondfo POCT) detects antibodies to the SARS-CoV-2 (the virus causing COVID-19).
The presence of antibodies to SARS-CoV-2 confirms exposure and is likely to convey immunity to COVID-19.
Cellmid expects the Wondfo POCT to be largely used to facilitate return to work programs.
The current shipment is intended to be sold to medical practitioners subject to the completion of internal testing.
A limited number of tests will be held for external testing and research purposes.
Second order planned
Cellmid has received several hundred enquiries and expressions of interest to supply the Wondfo POCT to medical practitioners, hospitals and research groups.
The company is currently evaluating these requests and will be completing confirmatory testing in preparation for placing its second order with the manufacturer.
The Cellmid sponsored Wondfo SARS-CoV-2 kit is manufactured in a facility certified by the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration (FDA) and the Chinese National Medical Products Administration (NMPA) under the Medical Device Single Audit Program (MDSAP) and is authorised to export its devices to Australia.